Johnson & Johnson (JNJ)
259.36
+5.57 (2.19%)
Upcoming Events
Latest Headlines
TD Cowen Reiterates Buy Rating on Johnson & Johnson (JNJ)
October 20, 2026 12:10 PM - StreetInsider
Johnson & Johnson launches faster coronary IVL catheter in the U.S.
October 20, 2026 7:46 AM - StreetInsider
Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
October 20, 2026 7:45 AM - BizWire
Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's
October 19, 2026 8:01 AM - StreetInsider
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
October 19, 2026 8:00 AM - PR NewsWire
Johnson & Johnson (JNJ) PT Raised to $287 at Wells Fargo
October 16, 2026 6:24 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $270 at Bernstein SocGen Group
October 15, 2026 8:27 AM - StreetInsider
Johnson & Johnson (JNJ) PT Lowered to $292 at Morgan Stanley
October 15, 2026 8:19 AM - StreetInsider
Johnson & Johnson (JNJ) PT Lowered to $280; RBC Capital: 'Excessive Sell-Off Creates Defensive Opportunity'
October 14, 2026 8:54 AM - StreetInsider
Johnson & Johnson (JNJ) PT Lowered to $275 at Wells Fargo
October 14, 2026 5:40 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $275 at BofA Securities
October 14, 2026 5:15 AM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Oct 13
October 13, 2026 8:13 AM - SEC Filing
Johnson & Johnson beats estimates, raises 2026 guidance
October 13, 2026 6:55 AM - StreetInsider
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026
October 13, 2026 6:25 AM - BizWire
Johnson & Johnson (JNJ) Declares $1.34 Quarterly Dividend; 2% Yield
October 13, 2026 6:25 AM - StreetInsider
Johnson & Johnson (JNJ) Tops Q3 EPS by 6c; adjusts forecast
October 13, 2026 6:21 AM - StreetInsider
Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
October 13, 2026 6:20 AM - BizWire
JNJ earnings preview Q3: weaker profit expected as biotech deals weigh
October 13, 2026 12:00 AM - StreetInsider
J&J's Tremfya shows fistula remission in Crohn's subgroups
October 12, 2026 4:06 PM - StreetInsider
J&J's Tremfya shows sustained remission in Crohn's at 3 years
October 12, 2026 4:05 PM - StreetInsider
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
October 12, 2026 4:05 PM - PR NewsWire
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
October 12, 2026 4:05 PM - PR NewsWire
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put into quarter results
October 12, 2026 10:50 AM - StreetInsider
Stifel Reiterates Hold Rating on Johnson & Johnson (JNJ)
October 12, 2026 9:25 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
October 12, 2026 6:27 AM - StreetInsider
Johnson & Johnson (JNJ) expiring October 9 weekly calls active into quarter results
October 9, 2026 11:16 AM - StreetInsider
Johnson & Johnson releases 2-year psoriasis drug data at dermatology meeting
October 9, 2026 7:01 AM - StreetInsider
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
October 9, 2026 7:00 AM - PR NewsWire
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
October 9, 2026 5:25 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.6 calls to 1 put into quarter results
October 8, 2026 5:37 AM - StreetInsider
2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
October 7, 2026 10:00 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
October 7, 2026 7:30 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $290 at RBC Capital
October 6, 2026 5:59 AM - StreetInsider
J&J releases 2-year icotrokinra data for hard-to-treat plaque psoriasis
October 2, 2026 6:03 AM - StreetInsider
Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic ther
October 2, 2026 6:00 AM - PR NewsWire
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause
October 1, 2026 7:45 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $13 at JPMorgan
September 29, 2026 8:41 AM - StreetInsider
J&J presents two-year IMAAVY data in adolescent myasthenia gravis
September 29, 2026 8:05 AM - StreetInsider
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)
September 29, 2026 8:03 AM - PR NewsWire
Johnson & Johnson (JNJ) PT Raised to $278 at BofA Securities
September 29, 2026 5:28 AM - StreetInsider
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) st
September 25, 2026 11:33 AM - PR NewsWire
J&J myeloma drug shows 5-year remission in half of early-line patients
September 25, 2026 11:32 AM - StreetInsider
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
September 25, 2026 11:32 AM - PR NewsWire
J&J myeloma drug combo shows survival gains in Phase 3 data
September 23, 2026 9:47 AM - StreetInsider
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in earl
September 23, 2026 9:47 AM - PR NewsWire
UBS Reiterates Buy Rating on Johnson & Johnson (JNJ)
September 22, 2026 9:29 AM - StreetInsider
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026
September 22, 2026 8:00 AM - BizWire
Johnson & Johnson's Caplyta meets primary endpoint in bipolar I mania trial
September 21, 2026 8:00 AM - StreetInsider
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study
September 21, 2026 8:00 AM - PR NewsWire
J&J lung cancer drug combo shows low side effect rates in study
September 15, 2026 6:04 AM - StreetInsider
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
September 14, 2026 11:00 PM - PR NewsWire
Johnson & Johnson lung cancer drug shows 34-month survival in phase 3 trial
September 14, 2026 4:30 AM - StreetInsider
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
September 13, 2026 9:45 PM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Sep 08 Filed by: Pinto Daniel E
September 10, 2026 8:51 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Sep 08 Filed by: Woods Eugene A.
September 10, 2026 8:51 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Sep 08 Filed by: HEWSON MARILLYN A
September 10, 2026 8:50 PM - SEC Filing
Johnson & Johnson gets CE mark for Acuvue Oasys MAX 2-Week lens
September 10, 2026 7:46 AM - StreetInsider
Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
September 10, 2026 7:45 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $320 at HSBC
September 10, 2026 3:28 AM - StreetInsider
Johnson & Johnson to present neuropsychiatry data at Psych Congress 2026
September 8, 2026 8:02 AM - StreetInsider
Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
September 8, 2026 8:00 AM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Sep 02 Filed by: Schmid Timothy
September 4, 2026 9:08 AM - SEC Filing
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
September 2, 2026 4:21 PM - BizWire
Form 144 JOHNSON & JOHNSON Filed by: Schmid Timothy
September 2, 2026 11:27 AM - SEC Filing
Form 3 JOHNSON & JOHNSON For: Sep 01 Filed by: Cavanaugh Thomas
September 1, 2026 4:53 PM - SEC Filing
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
August 31, 2026 5:08 PM - BizWire
FDA: issues early alert on Abiomed heart pump controller purge cassette issue
August 26, 2026 2:00 PM - StreetInsider
FDA approves Johnson & Johnson drug for rare blood disorder
August 24, 2026 7:13 PM - StreetInsider
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
August 24, 2026 7:12 PM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Aug 17 Filed by: Taubert Jennifer L
August 18, 2026 6:31 PM - SEC Filing
Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
August 18, 2026 7:40 AM - StreetInsider
Form 144 JOHNSON & JOHNSON Filed by: Taubert Jennifer L
August 17, 2026 12:51 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Aug 13 Filed by: Duato Joaquin
August 14, 2026 4:40 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Duato Joaquin
August 13, 2026 2:12 PM - SEC Filing
Intuitive Surgical: Oppenheimer now bullish, sees competition being "crowded out"
August 12, 2026 8:32 AM - StreetInsider
Form N-PX JOHNSON & JOHNSON For: Jun 30
August 11, 2026 6:01 AM - SEC Filing
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 10, 2026 4:27 PM - BizWire
Form 4 JOHNSON & JOHNSON For: Aug 05 Filed by: Duato Joaquin
August 7, 2026 5:51 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Aug 06 Filed by: Forminard Elizabeth
August 7, 2026 5:45 PM - SEC Filing
Morgan Stanley tracks US drug market prescriptions for week ending July 31
August 7, 2026 12:04 PM - StreetInsider
Form 144 JOHNSON & JOHNSON Filed by: Forminard Elizabeth
August 6, 2026 2:02 PM - SEC Filing
Form 13F-HR JOHNSON & JOHNSON For: Jun 30
August 6, 2026 10:46 AM - SEC Filing
Johnson & Johnson (JNJ) PT Raised to $287 at Guggenheim
August 6, 2026 6:44 AM - StreetInsider
Form 144 JOHNSON & JOHNSON Filed by: Duato Joaquin
August 5, 2026 6:08 PM - SEC Filing
Helus Pharma names ex-Intra-Cellular president as CEO
August 5, 2026 10:26 AM - StreetInsider
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 5, 2026 10:25 AM - Globe NewsWire
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
August 4, 2026 4:05 PM - BizWire
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
August 4, 2026 9:05 AM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Aug 04
August 4, 2026 8:49 AM - SEC Filing
Johnson & Johnson names Tom Cavanaugh to lead Innovative Medicine unit
August 4, 2026 8:45 AM - StreetInsider
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
August 4, 2026 8:45 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $280 at Raymond James
August 3, 2026 2:37 PM - StreetInsider
Microsoft joins, Broadcom exits Goldman's top-stocks list
August 3, 2026 8:01 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $282 at Wells Fargo
August 3, 2026 6:58 AM - StreetInsider
Goldman Monthly Update to US Director's Cut List
August 3, 2026 5:42 AM - StreetInsider
FDA grants priority review to J&J cancer drug for head and neck tumors
July 30, 2026 8:30 AM - StreetInsider
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advance
July 30, 2026 8:30 AM - PR NewsWire
Johnson & Johnson buys Firefly Bio for $1B to expand oncology work
July 29, 2026 5:42 PM - StreetInsider
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
July 29, 2026 5:42 PM - BizWire
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
July 29, 2026 5:28 PM - BizWire
Form 8-K JOHNSON & JOHNSON For: Jul 29
July 29, 2026 5:25 PM - SEC Filing
Covista adds two directors with healthcare and tech backgrounds
July 28, 2026 8:00 AM - StreetInsider
Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
July 28, 2026 8:00 AM - BizWire
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put unto J&J to settle ovarian talc claims
July 28, 2026 6:04 AM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Jul 27
July 28, 2026 6:03 AM - SEC Filing
Johnson & Johnson agrees to $5.5B settlement of ovarian talc claims
July 28, 2026 3:08 AM - StreetInsider
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
July 27, 2026 6:31 PM - BizWire
Form 10-Q JOHNSON & JOHNSON For: Jun 28
July 23, 2026 4:05 PM - SEC Filing
J&J myeloma drug combo cuts disease progression risk by 89% in trial
July 23, 2026 8:31 AM - StreetInsider
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
July 23, 2026 8:30 AM - PR NewsWire
FDA clears Johnson & Johnson's Ottava robotic surgical system
July 22, 2026 7:01 AM - StreetInsider
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
July 22, 2026 7:00 AM - BizWire
Full Article List
